Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q3 2025 · 10-Q
Revenue$231.10M$231.10M−21.3% vs Q3 2024 Net Income$51.20M$51.20M−55.4% vs Q3 2024 EPS Diluted$0.91$0.91−55.8% vs Q3 2024 Operating Income$76,500,000+18.6% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,700,000N/M Margins · derivedOperating margin33.1%+11.1 pt vs Q3 2024
Net margin22.2%−16.9 pt vs Q3 2024
ended Sep 30, 2025 · filed Oct 30, 2025 · 30 d after period end